Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology"
DOI: 10.1002/hep.30366
Abstract: Sorafenib is the most recommended first‐line systemic therapy for advanced hepatocellular carcinoma (HCC). Yet there is no clinically applied biomarker for predicting sorafenib response. We have demonstrated that a vascular pattern, named VETC (Vessels that… read more here.
Keywords: benefit; vetc; sorafenib benefit; tumor clusters ... See more keywords
Corrigendum to "Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies" [J hepatol 67 (2017) 999-1008].
Sign Up to like & getrecommendations! Published in 2018 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2018.07.015
Abstract: Hepatic Oncology, BCLC Hospital Clínic Barcelona, IDIBAPS, University of Barcelona CIBERehd, Barcelona, Spain; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA; Mount Sinai Liver Cancer Program, Icahn School… read more here.
Keywords: sorafenib benefit; prognostic factors; corrigendum prognostic; oncology ... See more keywords